Module

Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin

Source: Management of Depression and HCV: Novel Data, Best Practices, and Case Challenges

Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin


Faculty:

Martin Schaefer, MD
  • Martin Schaefer, MD

CME CREDIT INFORMATION

Release Date: 08/04/08

Expiration Date: 08/03/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status

Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the risk factors for and incidence of depression during interferon-based treatment for HCV infection
  • Discuss management strategies for depression in hepatitis C patients, including pretreatment assessment, prevention, and treatment
  • Recount the effects of HCV infection and treatment on cognition, sleep patterns, and mood
  • Describe the management of psychiatric disorders in hepatitis C patients with concurrent drug addiction

Topics covered include:

  • Introduction
  • Depression and Interferon alfa Treatment for HCV
  • Risk Factors for Neuropsychiatric Adverse Effects
  • Depression and Virologic Response
  • Pretreatment Assessment of Psychiatric Adverse Events
  • Pharmacological Treatment of Depression
  • Safety Aspects of Antidepressant Treatment
  • Preemptive Therapy With Antidepressants
  • Cognition, HCV Infection, and Treatment
  • Risk Factors, Diagnosis, and Management of Cognitive Impairment
  • Sleep Disturbances, Irritability, and Other Symptoms During Interferon Treatment
  • HCV Patients With Psychiatric Disorders in the Setting of Drug Addiction
  • Treatment Outcomes in Patients With Psychiatric Disorders and/or Drug Addiction
  • Clinical Management of HCV Therapy in Psychiatric Risk Patients
  • Summary and Conclusions
  • References
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.